Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Subcutaneous immunoglobulin: facilitated infusion and advances in administration.

× No keyword cloud information.

6 in total

Review 1. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration.

Authors: Gregory I Frost
Journal: Expert Opin Drug Deliv Date: 2007-07 Impact factor: 6.648

Review 2. Subcutaneous administration of IgG.

Authors: Melvin Berger
Journal: Immunol Allergy Clin North Am Date: 2008-11 Impact factor: 3.479

3. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis.

Authors: Ralph S Shapiro
Journal: Ann Allergy Asthma Immunol Date: 2013-05-22 Impact factor: 6.347

4. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency.

Authors: Richard L Wasserman; Isaac Melamed; Mark R Stein; Sudhir Gupta; Jennifer Puck; Werner Engl; Heinz Leibl; Barbara McCoy; Victoria G Empson; David Gelmont; Richard I Schiff
Journal: J Allergy Clin Immunol Date: 2012-07-28 Impact factor: 10.793

Review 5. Subcutaneous immunoglobulin replacement in primary immunodeficiencies.

Authors: Melvin Berger
Journal: Clin Immunol Date: 2004-07 Impact factor: 3.969

Review 6. Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies.

Authors: Richard L Wasserman
Journal: Immunotherapy Date: 2014 Impact factor: 4.196

6 in total

3 in total

1. Facilitated subcutaneous immunoglobulin treatment in pemphigus vulgaris.

Authors: Massimo Radin; Dario Roccatello; Simone Baldovino; Savino Sciascia
Journal: BMJ Case Rep Date: 2018-05-30

2. Direct and Indirect Costs of Immunoglobulin Replacement Therapy in Patients with Common Variable Immunodeficiency (CVID) and X-Linked Agammaglobulinemia (XLA) in Italy.

Authors: Raffaella Viti; Andrea Marcellusi; Alessandro Capone; Andrea Matucci; Alessandra Vultaggio; Claudio Pignata; Giuseppe Spadaro; Angelo Vacca; Carolina Marasco; Carlo Agostini; Francesco Saverio Mennini
Journal: Clin Drug Investig Date: 2018-10 Impact factor: 2.859

Review 3. ENHANZE^® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20

Authors: Kenneth W Locke; Daniel C Maneval; Michael J LaBarre
Journal: Drug Deliv Date: 2019-12 Impact factor: 6.419